14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today BCLI ranks #14567 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Brainstorm Cell Therapeutics Inc. Stock Forecast NASDAQ:BCLI

$3.32 (-2.06%)

Volume: 106k

Closed: Jan 19, 2022

Hollow Logo Score: -3.406

Brainstorm Cell Therapeutics Inc. Stock Forecast

$3.32 (-2.06%)

Volume: 106k

Closed: Jan 19, 2022

Score Hollow Logo -3.406

Brainstorm Cell Therapeutics Inc. Company Profile

3 University Plaza Drive

Hackensack NJ 07601



Industry: Biotechnology

Sector: Healthcare

Brainstorm Cell Therapeutics Inc.


Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE